Celyad announced that clinical data from the SHRINK and alloSHRINK Phase 1 trials, evaluating the safety of NKG2D-based autologous and allogeneic CAR-T candidates, CYAD-01 and CYAD-101, respectively, will be presented at the upcoming European Society for Medical Oncology, or ESMO world congress on Gastrointestinal Cancer, or WCGIC. CYAD-01 is an investigational CAR-T therapy in which a patient's T cells are engineered to express a chimeric antigen receptor, or CAR, based on NKG2D, a receptor expressed on natural killer cells that binds to eight stress-induced ligands expressed on tumor cells. CYAD-101 is an investigational, non-gene edited, allogeneic CAR-T therapy that co-expresses the NKG2D CAR of CYAD-01 and the novel inhibitory peptide TIM. The expression of TIM reduces signalling of the TCR complex which is responsible for Graft versus Host Disease. SHRINK is an open-label, dose-escalation Phase 1 trial assessing the safety and activity of CYAD-01 administered concurrently with Folfox chemotherapy in patients with metastatic colorectal cancer, or mCRC. Patients will receive six cycles of Folfox chemotherapy every two weeks and three administrations of CYAD-01 every two weeks. alloSHRINK is an open-label, dose-escalation Phase 1 trial assessing the safety and clinical activity of CYAD-101 administered concurrently with Folfox chemotherapy in patients with refractory mCRC. Similar to the SHRINK trial for CYAD-01, patients will receive six cycles of Folfox chemotherapy every two weeks and three administrations of CYAD-101 every two weeks.
